Gender Differences in Epidemiology, Pathophysiology, and Treatment of Hypertension

  • Paolo Di Giosia
  • Paolo Giorgini
  • Cosimo Andrea Stamerra
  • Marco Petrarca
  • Claudio Ferri
  • Amirhossein Sahebkar
Women and Ischemic Heart Disease (A. Maran, Section Editor)
  • 102 Downloads
Part of the following topical collections:
  1. Topical Collection on Women and Ischemic Heart Disease

Abstract

Purpose of Review

This review aims to examine gender differences in both the epidemiology and pathophysiology of hypertension and to explore gender peculiarities on the effects of antihypertensive agents in decreasing BP and CV events.

Recent Findings

Men and women differ in prevalence, awareness, and control rate of hypertension in an age-dependent manner. Studies suggest that sex hormones changes play a pivotal role in the pathophysiology of hypertension in postmenopausal women. Estrogens influence the vascular system inducing vasodilatation, inhibiting vascular remodeling processes, and modulating the renin-angiotensin aldosterone system and the sympathetic system. This leads to a protective effect on arterial stiffness during reproductive age that is dramatically reversed after menopause.

Summary

Data on the efficacy of antihypertensive therapy between genders are conflicting, and the underrepresentation of aged women in large clinical trials could influence the results. Therefore, further clinical research is needed to uncover potential gender differences in hypertension to promote the development of a gender-oriented approach to antihypertensive treatment.

Keywords

Hypertension Blood pressure Cardiovascular risk Gender Treatment disparities 

Notes

Compliance with Ethical Standards

Conflict of Interest

Paolo Di Giosia, Paolo Giorgini, Cosimo Andrea Stamerra, Marco Petrarca, Claudio Ferri, and Amirhossein Sahebkar declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–323.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Burl VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25:305–13.CrossRefGoogle Scholar
  3. 3.
    Marcus R, Krause L, Weder AB, Dominguez-Mejia, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation. 1994;90:928–36.CrossRefPubMedGoogle Scholar
  4. 4.
    Tofler GH, Stone PH, Muller JE, the MILIS Study Group, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, especially black women. J Am Coll Cardiol. 1987;9(3):473–82.  https://doi.org/10.1016/S0735-1097(87)80038-4.CrossRefPubMedGoogle Scholar
  5. 5.
    Karlson BW, Herlitz J, Hartford M. Prognosis in myocardial infarction in relation to gender. Am Heart J. 1994;128:477–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Hayward CS, Kelly RP. Gender-related differences in the central arterial pressure waveform. J Am Coll Cardiol. 1997 Dec;30(7):1863–71.  https://doi.org/10.1016/S0735-1097(97)00378-1.CrossRefPubMedGoogle Scholar
  7. 7.
    Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112(15):2254–62.  https://doi.org/10.1161/CIRCULATIONAHA.105.541078.CrossRefPubMedGoogle Scholar
  8. 8.
    Everett B, Zajacova A. Gender differences in hypertension and hypertension awareness among young adults. Biodemography Soc Biol. 2015;61:1–17.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Doumas M, Papademetriou V, Faselis C, Kokkinos P. Gender differences in hypertension: myths and reality. Curr Hyperten Rep. 2013;15(4):321–30.  https://doi.org/10.1007/s11906-013-0359-y.CrossRefGoogle Scholar
  10. 10.
    Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598–615.CrossRefPubMedGoogle Scholar
  11. 11.
    Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.CrossRefPubMedGoogle Scholar
  12. 12.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Circulation. 2013;127(1):143–52.Google Scholar
  13. 13.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.CrossRefPubMedGoogle Scholar
  14. 14.
    Robitaille C, Dai S, Waters C, Loukine L, Bancej C, Quach S, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ. 2012;184:E49–56.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Prince MJ, Ebrahim S, Acosta D, Ferri CP, Guerra M, Huang Y, et al. Hypertension prevalence, awareness, treatment and control among older people in Latin America, India and China: a 10/66 cross-sectional population-based survey. J Hypertens. 2012 Jan;30(1):177–87.  https://doi.org/10.1097/HJH.0b013e32834d9eda.CrossRefPubMedGoogle Scholar
  16. 16.
    Tocci G, Ferrucci A, Pontremoli R, Ferri C, Rosei EA, Morganti A, et al. Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000–2005 and 2005–2011 hypertension surveys. J Hum Hypertens. 2015;29(11):696–701.  https://doi.org/10.1038/jhh.2015.4.CrossRefPubMedGoogle Scholar
  17. 17.
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.  https://doi.org/10.1016/S0140-6736(05)70151-3.CrossRefPubMedGoogle Scholar
  18. 18.
    Lloyd-Jones DM, Evans JC, Levy D, et al. JAMA. 2005;294:466–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe 2015: epidemiological update. Eur Heart J. 2015;36(40):2673–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Mosca L, Benjamin EJ, Berra K, Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–62.  https://doi.org/10.1161/CIR.0b013e31820faaf8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Casiglia E, Tikhonoff V, Caffi S, Bascelli A, Schiavon L, Guidotti F, et al. Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. J Hypertens. 2008;26(10):1983–92.  https://doi.org/10.1097/HJH.0b013e32830bfdd9.CrossRefPubMedGoogle Scholar
  23. 23.
    Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirrelli A, Sega R, et al. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens. 2005;23(12):2269–76.  https://doi.org/10.1097/01.hjh.0000194118.35098.43.CrossRefPubMedGoogle Scholar
  24. 24.
    Cifkowa R, Pitha J, Lejskova M, Lanska V, Zecova S. Blood pressure around the menopause: a population study. J Hypertens. 2008;26(10):1976–82.  https://doi.org/10.1097/HJH.0b013e32830b895c.CrossRefGoogle Scholar
  25. 25.
    Mongraw-Chaffin M, Cirillo P, Cohn B. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166–71. 2011; 123:1243–62CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53(6):944–51.CrossRefPubMedGoogle Scholar
  27. 27.
    McDonald S, Malinowski A, Zhou Q, Yusuf S, Devereaux P. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156(5):918–30.  https://doi.org/10.1016/j.ahj.2008.06.042.CrossRefPubMedGoogle Scholar
  28. 28.
    Bellamy L, Casas J, Hingorani A, Williams D. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974–86.  https://doi.org/10.1136/bmj.39335.385301.BE.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA. 2002;287(8):1003–10.CrossRefPubMedGoogle Scholar
  30. 30.
    Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 2009;302(4):401–11.  https://doi.org/10.1001/jama.2009.1060.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Schiller J, Lucas J, Peregoy J. Summary health statistics for US adults: National Health Interview Survey 2010. Vital Health Stat. 2012;252:1–207.Google Scholar
  32. 32.
    Bursztyn M, Ben-Dov I. Sex differences in salt-sensitivity risk approximated from ambulatory blood pressure monitoring and mortality. J Hypertens. 2013;31(5):900–5.  https://doi.org/10.1097/HJH.0b013e32835f29f4.CrossRefPubMedGoogle Scholar
  33. 33.
    Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51(4):1142–8.  https://doi.org/10.1161/HYPERTENSIONAHA.107.105205.CrossRefPubMedGoogle Scholar
  34. 34.
    Franco O, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46(2):280–6.  https://doi.org/10.1161/01.HYP.0000173433.67426.9b.CrossRefPubMedGoogle Scholar
  35. 35.
    Redon J, Olsen M, Cooper R, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J. 2011;32(11):1424–31.  https://doi.org/10.1093/eurheartj/ehr045.CrossRefPubMedGoogle Scholar
  36. 36.
    Wieberdink R, Ikram M, Hofman A, Koudstaal P, Breteler M. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol. 2012;27(4):287–95.  https://doi.org/10.1007/s10654-012-9673-y.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Martinez-Selles M, Doughty R, Poppe K, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient metaanalysis. Eur J Heart Fail. 2012;14:473–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens. 1989;3(6):427–33.PubMedGoogle Scholar
  39. 39.
    Amigoni S, Morelli P, Parazzini F, Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy. Maturitas. 2000;34(1):25–32.  https://doi.org/10.1016/S0378-5122(99)00089-4.CrossRefPubMedGoogle Scholar
  40. 40.
    Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708.CrossRefPubMedGoogle Scholar
  41. 41.
    Komukai K, Mochizuki S, Yoshimura M. Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol. 2010;24(6):687–98.  https://doi.org/10.1111/j.1472-8206.2010.00854.x.CrossRefPubMedGoogle Scholar
  42. 42.
    Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53(3):672–7.  https://doi.org/10.1016/S0008-6363(01)00479-5.CrossRefPubMedGoogle Scholar
  43. 43.
    Sullivan JC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul, Integr Comp Physiol. 2008;294(4):R1220–6.  https://doi.org/10.1152/ajpregu.00864.2007.CrossRefGoogle Scholar
  44. 44.
    Hernandez Schulman I, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol. 2006;26(2):170–80.  https://doi.org/10.1159/000092984.CrossRefPubMedGoogle Scholar
  45. 45.
    Pechere-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;1(7):994–1001.CrossRefGoogle Scholar
  46. 46.
    Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47(6):1168–74.  https://doi.org/10.1161/01.HYP.0000218857.67880.75.CrossRefPubMedGoogle Scholar
  47. 47.
    Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54(1):11–8.  https://doi.org/10.1161/HYPERTENSIONAHA.108.120022.CrossRefPubMedGoogle Scholar
  48. 48.
    Nuzzo A, Rossi R, Modena MG. Hypertension alone or related to the metabolic syndrome in postmenopausal women. Expert Rev Cardiovasc Ther. 2010;8:1541Y1548.CrossRefGoogle Scholar
  49. 49.
    Rossi P, Frances Y, Kingwell BA, et al. Gender differences in artery wall biomechanical properties throughout life. J Hypertens. 2011;29:1023–33.CrossRefPubMedGoogle Scholar
  50. 50.
    Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A. Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens. 1997;15(6):591–600.  https://doi.org/10.1097/00004872-199715060-00004.CrossRefPubMedGoogle Scholar
  51. 51.
    Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens. 1998;16(10):1545–53.  https://doi.org/10.1097/00004872-199816100-00021.CrossRefPubMedGoogle Scholar
  52. 52.
    Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7(11):1012–5.  https://doi.org/10.1093/ajh/7.11.1012.CrossRefPubMedGoogle Scholar
  53. 53.
    Kajiwara A, Saruwatari J, Kita A, Oniki K, Yamamura M, Murase M, et al. Younger females are at greater risk of vasodilation-related adverse symptoms caused by dihydropyridine calcium channel blockers: results of a study of 11,918 Japanese patients. Clin Drug Investig. 2014;34(6):431–5.  https://doi.org/10.1007/s40261-014-0191-4.CrossRefPubMedGoogle Scholar
  54. 54.
    Pemu PI, Ofili E. Hypertension in women—part I. J Clin Hypertens (Greenwich). 2008;10:406–10.CrossRefPubMedCentralGoogle Scholar
  55. 55.
    Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003;139:476–82.CrossRefPubMedGoogle Scholar
  56. 56.
    Turnbull F, Woodward M, Anna V. Effectiveness of blood pressure lowering: evidence-based comparisons between men and women. Expert Rev Cardiovasc Ther. 2010;8(2):199–209.  https://doi.org/10.1586/erc.09.155.CrossRefPubMedGoogle Scholar
  57. 57.
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.  https://doi.org/10.1016/S0140-6736(02)08089-3.CrossRefPubMedGoogle Scholar
  58. 58.
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–31.  https://doi.org/10.1016/S0140-6736(04)16451-9.CrossRefPubMedGoogle Scholar
  59. 59.
    Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.  https://doi.org/10.1016/S0140-6736(05)67185-1.CrossRefPubMedGoogle Scholar
  60. 60.
    Kloner R, Sowers J, DiBona G, et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77:713–22.CrossRefPubMedGoogle Scholar
  61. 61.
    Saunders E, Cable G, Neutel J. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study. J Clin Hypertens (Greenwich). 2008;10(1):27–33.  https://doi.org/10.1111/j.1524-6175.2007.07195.x.CrossRefGoogle Scholar
  62. 62.
    Everett BM, Glynn RJ, Danielson E, Ridker PM. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther. 2008;30(4):661–72.  https://doi.org/10.1016/j.clinthera.2008.04.013.CrossRefPubMedGoogle Scholar
  63. 63.
    Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24(11):2163–8.  https://doi.org/10.1097/01.hjh.0000249692.96488.46.CrossRefPubMedGoogle Scholar
  64. 64.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.  https://doi.org/10.1001/jama.288.23.2981.CrossRefGoogle Scholar
  65. 65.
    Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51(4):1103–8.  https://doi.org/10.1161/HYPERTENSIONAHA.107.105296.CrossRefPubMedGoogle Scholar
  66. 66.
    Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29(21):2669–80.  https://doi.org/10.1093/eurheartj/ehn427.CrossRefPubMedGoogle Scholar
  67. 67.
    • Giorgini P, Sahebkar A, Stamerra CA, Raparelli V, Petrarca M, Grassi D, et al. Comparison of clinical outcomes between genders following antihypertensive therapy: a meta-analysis. Curr Med Chem. 2017;24(24):2639–49. This paper represents the most recent meta-analysis on gender differences in clinical outcomes following antihypertensive therapy. CrossRefPubMedGoogle Scholar
  68. 68.
    SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.CrossRefGoogle Scholar
  69. 69.
    •• Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017. Recently updated guidelines for management of hypertension. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Paolo Di Giosia
    • 1
  • Paolo Giorgini
    • 1
  • Cosimo Andrea Stamerra
    • 1
  • Marco Petrarca
    • 1
  • Claudio Ferri
    • 1
  • Amirhossein Sahebkar
    • 2
    • 3
  1. 1.Department of Life, Health & Environmental SciencesUniversity of L’AquilaL’AquilaItaly
  2. 2.Biotechnology Research Center, Pharmaceutical Technology InstituteMashhad University of Medical SciencesMashhadIran
  3. 3.Neurogenic Inflammation Research CenterMashhad University of Medical SciencesMashhadIran

Personalised recommendations